Biomarker Discovery & Validation: Page 2

QMC Health, Lawson Health Research ink agreement for long-COVID blood biomarkers

With blood biomarkers acquired in an agreement with Lawson Health Research Institute, QMC Health plans to develop a point-of-care rapid test using its QDX HPFIS technology.

November 1, 2022

Quest Diagnostics, Decode Health expand collaboration on biomarker discovery to MS, NAFLD

At this stage of the collaboration, the companies will focus on early detection, differential diagnosis, and therapy selection for multiple sclerosis (MS) and nonalcoholic fatty liver disease (NAFLD).

October 18, 2022

Renalytix to present at American Society of Nephrology Kidney Week

The presentations will include a cost-effectiveness analysis supporting population-based KidneyIntelX testing for Medicare patients, as well as findings from a multiyear study at a major healthcare system highlighting disparities in healthcare access.

October 17, 2022

Oni, University of Pennsylvania to collaborate on CAR-T therapy research

Oni's Nanoimager super-resolution microscopy will allow researchers to visualize living cells and observe how single molecules interact.

October 11, 2022

Bio-Techne releases automated codetection assays for Roche platform

Developed in partnership with Roche, the new automated multiomic assays use Bio-Techne's patented RNAscope and BaseScope signal amplification and background suppression technologies.

October 6, 2022

Qiagen, Neuron23 to develop CDx for Parkinson’s

Under the agreement, Qiagen will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to a LRRK2 inhibitor.

September 13, 2022

Nucleai, Sirona Dx partner on tumor biomarker discovery

The partnership combines Nucleai's artificial intelligence (AI) spatial analytics platform with Sirona Dx's multiplex assay development expertise to identify novel spatial signatures in high-plex assays that predict responses to therapy and inform treatment decisions.

July 13, 2022

Boehringer Ingelheim, BiomX partner on IBD biomarkers

BiomX said that under the collaboration, it will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD.

June 27, 2022

Spinal fluid tests may aid PET scans of Alzheimer's disease

A Swiss group led by senior author Michael Schöll, PhD, of the University Gothenburg investigated whether fluid and blood biomarkers that indicate Alzheimer's disease could predict the accumulation of neurofibrillary tau tangles seen on PET scans in patients diagnosed with the disease. They found the lab tests performed well enough to help select patients for PET imaging studies evaluating new treatments.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Brain surface renderings depict Pearson correlation coefficients adjusted for age and sex (r) representing the strength of the association between the different biomarkers and F-18 flortaucipir SUVR change in each brain region. The right upper panel represents age- and sex-adjusted Pearson correlation coefficients (r), along with p-values, for the association between the biomarkers and F-18 flortaucipir SUVR change in the Alzheimer's disease meta-region of interest (ROI). The root mean squared error (RMSE) for the prediction of F-18 flortaucipir SUVR change by a linear model with the biomarker as predictor and age and sex as covariates. RMSE was estimated using leave-one-out cross-validation. Voxel-wise statistical maps were thresholded using more lenient cluster-forming thresholds of p < 0.05 (uncorrected) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

March 3, 2022

SLAS 2022: Diagnostics tech should be based on clinical need

Traditionally, scientists and engineers create a technology, find a biological application for it, and publish it in a big academic journal. For companies, the cycle is a bit different: a company creates a technology, most likely for life sciences research, and then years (if not decades) later, someone discovers a clinical application for it.

February 9, 2022

SQI, Owlstone partner on breath-based biomarkers for lung tests

Under the MOU, the companies will agree on regulatory strategies for independent clinical trials being conducted by Owlstone. The trials are testing the validation of breath-based volatile organic compounds to diagnose invasive aspergillosis.

January 24, 2022

Tau blood test shows promise for very early Alzheimer's detection

One study was conducted at the lab of Dr. Randall Bateman, a Charles F. and Joanne Knight distinguished professor of neurology at Washington University in St. Louis. Researchers evaluated a mass spectrometry test for assessment of p-tau-217 and other tau fragments using small blood samples -- as small as 4 mL.

July 28, 2020

Previous Page

Page 2 of 3

Next Page